N/A (ifosfamide, carboplatin, etoposide regimen)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for N/A (ifosfamide, carboplatin, etoposide regimen), covering 2023-04-12 to 2023-04-12. Get the full timeline:
Most recent: Clinical Trial Update: A Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab at the Fixed Dose 40 mg, Ifosfamide, Carboplatin, Etoposide (NICE-40) in Patients With Relapsed/Refractory Hodgkin Lymphoma [Phase 1, Phase 2]